Ohio State is in the process of revising websites and program materials to accurately reflect compliance with the law. While this work occurs, language referencing protected class status or other activities prohibited by Ohio Senate Bill 1 may still appear in some places. However, all programs and activities are being administered in compliance with federal and state law.

Nicolas Denko

Nicolas Denko

Nicolas Denko

Contact Information

Professor, Department of Radiation Oncology

Education

  • PhD: University of Cincinnati

The Denko Lab studies the role of the tumor microenvironment on malignant progression and resistance to therapy. Specifically, we study tumor hypoxia and its impact on metabolism, mitochondrial function, resistance to radiotherapy and immunotherapy. We have developed the used o mitochondrial inhibitors as a means of reducing tumor hypoxia resulting in increased tumor sensitivity. We have a repurposed FDA-approved drug in clinical trial for the treatment of NSCLC, and are developing second generation molecules with reduced normal tissue toxicities.